Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Income from Continuing Operations (2017 - 2025)

Autolus Therapeutics' Income from Continuing Operations history spans 6 years, with the latest figure at 90332000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 227.22% year-over-year to 90332000.0; the TTM value through Dec 2025 reached 287528000.0, down 30.3%, while the annual FY2025 figure was 287528000.0, 30.3% down from the prior year.
  • Income from Continuing Operations reached 90332000.0 in Q4 2025 per AUTL's latest filing, down from 79118000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 26979000.0 in Q4 2022 to a low of 90332000.0 in Q4 2025.
  • Average Income from Continuing Operations over 4 years is 54090000.0, with a median of 46883000.0 recorded in 2023.
  • Peak YoY movement for Income from Continuing Operations: surged 64.23% in 2024, then tumbled 227.22% in 2025.
  • A 4-year view of Income from Continuing Operations shows it stood at 26979000.0 in 2022, then plummeted by 186.04% to 77171000.0 in 2023, then soared by 64.23% to 27606000.0 in 2024, then crashed by 227.22% to 90332000.0 in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Income from Continuing Operations are 90332000.0 (Q4 2025), 79118000.0 (Q3 2025), and 47917000.0 (Q2 2025).